Diagnostic Value of Recombinant Human Thyrotropin–Stimulated 123I Whole-Body Scintigraphy in the Follow-Up of Patients With Differentiated Thyroid Cancer
Authors:
- Ali S. AlzahraniAAAli S. Alzahrani
- OmAlkhaire AlShaikhOAOmAlkhaire AlShaikh
- Mahmoud TuliMTMahmoud Tuli
- Abdulaziz Al-SugairAAAbdulaziz Al-Sugair
- Reem AlamawiRAReem Alamawi
- Maha M. Al-RasheedMAMaha M. Al-Rasheed
- 1 March 2012
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 37 (3) , 229-234
Abstract
Published data on recombinant human thyrotropin- (rhTSH-) stimulated iodine-123 (¹²³I) diagnostic whole-body scintigraphy (DxWBS) in differentiated thyroid cancer (DTC) surveillance after initial treatment are limited. We sought to evaluate this modality's diagnostic value in this setting. We retrospectively compared rhTSH-stimulated ¹²³I DxWBS results with DTC status concurrently determined by stimulated serum thyroglobulin (Tg) measurement, neck ultrasonography, and other imaging studies. Disease was considered present based on stimulated Tg level ≥1 μg/L without interfering Tg autoantibodies with or without positive imaging or biopsy-proven DTC. We also compared scan positivity and disease detection rates of rhTSH-stimulated DxWBS scans obtained with ¹²³I with those acquired with iodine-131 (¹³¹I) during the same period. The sample comprised 105 consecutive totally thyroidectomized patients undergoing rhTSH-aided DxWBS with I-123 (n = 67) or with ¹³¹I (n = 38) for diagnostic follow-up. rhTSH, 0.9 mg/d, was injected intramuscularly on 2 consecutive days. Oral diagnostic activities of 5 to 10 mCi (185-370 MBq) ¹²³I or 3 mCi (111 MBq) ¹³¹I were given on the third day. DxWBS was performed 24 hours (¹²³I) or 48 to 72 hours (¹³¹I) later. rhTSH-aided ¹²³I DxWBS scans showed 35.3% sensitivity, 98.0% specificity, 85.7% positive predictive value, and 81.6% negative predictive value. rhTSH-stimulated ¹²³I and ¹³¹I DxWBS did not differ in scan positivity (10.4% vs. 13.2%, P = 0.75) or disease detection rates (35.3% vs. 27.8%, P = 1.00). In DTC, rhTSH-aided ¹²³I DxWBS achieves comparable results in diagnostic follow-up with those of rhTSH-aided ¹³¹I DxWBS. Future studies should address the preablation setting and scan activity and timing.Keywords
This publication has 19 references indexed in Scilit:
- Iodine Biokinetics and Radioiodine Exposure after Recombinant Human Thyrotropin-Assisted Remnant Ablation in Comparison with Thyroid Hormone WithdrawalThe Journal of Clinical Endocrinology & Metabolism, 2010
- Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid CancerThyroid®, 2009
- A Comparison Between Diagnostic I-123 and Posttherapy I-131 Scans in the Detection of Remnant and Locoregional Thyroid DiseaseClinical Nuclear Medicine, 2009
- Expanding Indications for Recombinant Human TSH in Thyroid CancerThyroid®, 2008
- Timing of Iodine-123 Scintigraphy Following Use of Recombinant Human Thyrotropin in Differentiated Thyroid CarcinomaClinical Nuclear Medicine, 2007
- Comparative Evaluation of Recombinant Human Thyrotropin-Stimulated Thyroglobulin Levels,131I Whole-Body Scintigraphy, and Neck Ultrasonography in the Follow-Up of Patients with Papillary Thyroid Microcarcinoma Who Have Not Undergone Radioiodine TherapyThe Journal of Clinical Endocrinology & Metabolism, 2006
- Recombinant Human Thyrotropin-Stimulated Serum Thyroglobulin Combined with Neck Ultrasonography Has the Highest Sensitivity in Monitoring Differentiated Thyroid CarcinomaThe Journal of Clinical Endocrinology & Metabolism, 2003
- A Consensus Report of the Role of Serum Thyroglobulin as a Monitoring Method for Low-Risk Patients with Papillary Thyroid CarcinomaThe Journal of Clinical Endocrinology & Metabolism, 2003
- Comparison of I-123 and I-131 for Whole-Body Imaging After Stimulation by Recombinant Human ThyrotropinClinical Nuclear Medicine, 2003
- Comparison of Administration of Recombinant Human Thyrotropin with Withdrawal of Thyroid Hormone for Radioactive Iodine Scanning in Patients with Thyroid CarcinomaNew England Journal of Medicine, 1997